Complement C1qB Chain (C1QB, C+A− quadrant), Increased C1QB expression decreases the effectiveness of combined Ibrutinib and Venetoclax in patients with Mantle-Cell lymphoma (a B-cell lymphoma) and is associated with a worse prognosis [91]. Here, C1QB is linked to B-cell non-Hodgkin lymphoma.